Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRG 1801

Next Previous
X
Search
Drug Profile

PRG 1801

Alternative Names: BCMA CAR-T cell therapy - Pregene Shenzhen Biotechnology; BCMA nano-antibody CAR-T cell therapy - Pregene Shenzhen Biotechnology; PRG-1801

Latest Information Update: 31 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pregene ShenZhen Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase 0 Lupus nephritis
  • Clinical Phase Unknown Anti-neutrophil cytoplasmic antibody-associated vasculitis

Most Recent Events

  • 15 Jul 2024 Wuhan Union Hospital plans a phase 0 (Early phase I) trial for Thrombocytopenia in China (IV, Infusion) (NCT06519565)
  • 01 Jul 2024 Phase-0 for Lupus nephritis (Treatment-resistant) in China (Parenteral) (NCT06497387)
  • 05 Feb 2024 Clinical trials in Anti-neutrophil cytoplasmic antibody-associated vasculitis (Treatment-resistant) in China (Parenteral) (NCT06277427)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top